MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Up 144.9% in December

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 1,685,137 shares, an increase of 144.9% from the November 30th total of 687,986 shares. Based on an average daily volume of 1,479,960 shares, the short-interest ratio is presently 1.1 days. Approximately 6.7% of the company’s shares are sold short. Approximately 6.7% of the company’s shares are sold short. Based on an average daily volume of 1,479,960 shares, the short-interest ratio is presently 1.1 days.

Insider Activity at MAIA Biotechnology

In related news, CEO Vlad Vitoc purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The stock was bought at an average cost of $1.14 per share, with a total value of $57,000.00. Following the completion of the purchase, the chief executive officer directly owned 881,421 shares in the company, valued at approximately $1,004,819.94. This represents a 6.01% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Stan Smith acquired 57,189 shares of the stock in a transaction on Monday, December 22nd. The stock was bought at an average price of $1.22 per share, with a total value of $69,770.58. Following the completion of the acquisition, the director directly owned 1,421,478 shares of the company’s stock, valued at $1,734,203.16. This trade represents a 4.19% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders bought 368,352 shares of company stock valued at $427,192. 32.32% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Centerpoint Advisory Group purchased a new stake in shares of MAIA Biotechnology in the second quarter worth $28,000. Marshall Wace LLP purchased a new position in shares of MAIA Biotechnology in the 2nd quarter worth about $29,000. Jane Street Group LLC bought a new position in MAIA Biotechnology in the 2nd quarter worth about $52,000. Geode Capital Management LLC grew its position in MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after purchasing an additional 7,746 shares during the last quarter. Finally, Centric Wealth Management grew its position in MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after purchasing an additional 505,150 shares during the last quarter. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Price Performance

NYSEAMERICAN:MAIA traded up $0.09 during mid-day trading on Friday, hitting $1.57. 761,956 shares of the company’s stock were exchanged, compared to its average volume of 977,358. The company has a market cap of $58.14 million and a PE ratio of -2.15. MAIA Biotechnology has a one year low of $0.87 and a one year high of $2.74. The business has a fifty day moving average price of $1.22 and a 200 day moving average price of $1.50.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its earnings results on Friday, November 7th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). On average, equities analysts forecast that MAIA Biotechnology will post -1.3 EPS for the current fiscal year.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.